Barely Significant
← all excerpts

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.

Neurology · 2015 · PMC4408283 · PMID 25795646

Europe PMCDOI
1
hedged sentence
0.0643
closest p · 1.3× alpha
0.0643
boldest claim

The sentences

showed a trendp = 0.0643so close (0.05 < p ≤ 0.1)
When the same within-group comparison was made in the 48-month completer population, the reduction in ARR was significant in the placebo–fingolimod 0.5 mg switch group ( p < 0.0001), and showed a trend toward reduction in the placebo–fingolimod 1.25 mg switch group ( p = 0.0643).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.